Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 10/20 | 0.56 |
| ▸ | MEN1 | O00255 | 9/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | TNF | P01375 | 2/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.49 |
| ▸ | POLA1 | P09884 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837358 | 0.90 | SYK (0.52) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL30879330 | 0.87 | HTT (0.51) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL30878680 | 0.82 | SYK (0.72) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL17837350 | 0.82 | SYK (0.72) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL30878987 | 0.80 | HTT (0.58) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL13498137 | 0.78 | EGFR (0.53) | KMT2AMEN1RAB9ANPC1EGFR | |
| SCHEMBL19441968 | 0.77 | SYK (0.55) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL16824949 | 0.76 | RXFP1 (0.53) | KMT2AMEN1ALDH1A1EGFRBTK | |
| SCHEMBL15992367 | 0.76 | SYK (0.57) | KMT2AMEN1ALDH1A1RAB9ANPC1 | |
| SCHEMBL6996215 | 0.74 | ABCG2 (0.57) | EGFRABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | DANA FARBER CANCER INSTITUTE, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2019-08-22 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-28 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| EP-3019491-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | Dana-Farber Cancer Institute, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015006492-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256475-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | KMT2A 1697/4885MEN1 3935/4885ALDH1A1 3876/4885 |
| US-20170369449-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | KMT2A 1697/4885MEN1 3935/4885ALDH1A1 3876/4885 |
| US-10906878-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | KMT2A 1697/4885MEN1 3935/4885ALDH1A1 3876/4885 |
| US-10316002-B2 | Kinase inhibitors for the treatment of disease | BLK, ROS1, TEC | KMT2A 1697/4885MEN1 3935/4885ALDH1A1 3876/4885 |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | KMT2A 1697/4885MEN1 3935/4885ALDH1A1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.